N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.
Sara M. Tolaney,Nan Lin,Donald Thornton,Suzanne Klise,Timothy M. Costigan,P. Kellie Turner,Carey K. Anders +6 more
TL;DR: An open-label, Phase 2, Simon 2-Stage trial evaluating the safety and efficacy of abemaciclib 200 mg BID in pts with new or progressive BM secondary to HR+ MBC, NSCLC, or melanoma.
Journal ArticleDOI
Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study: a pragmatic, randomised clinical trial
Troy S. Wildes,Anke C. Winter,Hannah R. Maybrier,Angela M. Mickle,Eric J. Lenze,Susan Stark,Nan Lin,Sharon K. Inouye,Eva M. Schmitt,Sherry L. McKinnon,Maxwell R. Muench,Matthew R. Murphy,Ravi T Upadhyayula,Bradley A. Fritz,Krisztina E Escallier,Ginika P Apakama,Daniel A. Emmert,Thomas J. Graetz,Toer W. Stevens,Ben J.A. Palanca,R L Hueneke,Spencer J. Melby,Brian A. Torres,J Leung,E Jacobsohn,Michael S. Avidan +25 more
TL;DR: It is hypothesised that EEG-guidance of anaesthetic administration prevents postoperative delirium and downstream sequelae, including falls and decreased quality of life, in patients older than 60 after a major operation.
Journal ArticleDOI
Novel protective role of the circadian nuclear receptor retinoic acid-related orphan receptor-α in diabetic cardiomyopathy
TL;DR: Cardiac‐targeted manipulation of nuclear melatonin receptor RORα may hold promise for delaying diabetic cardiomyopathy development.
Journal ArticleDOI
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro,Cristina Saura,Cristina Saura,Romualdo Barroso-Sousa,Hao Guo,Eva Ciruelos,Begoña Bermejo,Joaquín Gavilá,Violeta Serra,Aleix Prat,Laia Paré,Pamela Céliz,Patricia Villagrasa,Yisheng Li,Jennifer Savoie,Zhan Xu,Carlos L. Arteaga,Ian E. Krop,David B. Solit,Gordon B. Mills,Gordon B. Mills,Lewis C. Cantley,Eric P. Winer,Nan Lin,Jordi Rodon,Jordi Rodon,Jordi Rodon +26 more
TL;DR: Buparlisib was associated with prolonged SD in a very small subset of patients with triple-negative breast cancer; however, no confirmed objective responses were observed.
Journal ArticleDOI
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
Andres Forero-Torres,Katherine E. Varley,Vandana G. Abramson,Yufeng Li,Christos Vaklavas,Nan Lin,Minetta C. Liu,Hope S. Rugo,Rita Nanda,Anna Maria Storniolo,Tiffany A. Traina,Sujata Patil,Catherine Van Poznak,Julie R. Nangia,William J. Irvin,Helen Krontiras,Jennifer F. De Los Santos,Paul Haluska,William E. Grizzle,Richard M. Myers,Antonio C. Wolff +20 more
TL;DR: Preclinical activity of TIG in basal-like breast cancer and prolonged PFS in few patients in the combination arm support further investigation of anti-DR5 agents and Exploratory analysis suggests an association of ROCK1 gene pathway activation with efficacy in the TIG/nab-PAC arm.